thalidomide has been researched along with Cancer of Esophagus in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period." | 6.71 | Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| "Thalidomide was well tolerated by EC patients." | 2.79 | Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. ( Hu, LJ; Li, DQ; Li, Y; Ni, XC; Sun, SP; Sun, ZQ; Wang, J; Yu, JP, 2014) |
| "Oesophageal cancer cachexia is a significant clinical problem, resulting in excessive morbidity and mortality." | 2.76 | Poor tolerability of thalidomide in end-stage oesophageal cancer. ( Cole, AT; Freeman, JG; Khan, ZH; Rennie, MJ; Selby, AL; Wilkes, EA, 2011) |
| "Thalidomide treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period." | 2.71 | Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, JP | 1 |
| Sun, SP | 1 |
| Sun, ZQ | 1 |
| Ni, XC | 1 |
| Wang, J | 1 |
| Li, Y | 1 |
| Hu, LJ | 1 |
| Li, DQ | 1 |
| Ong, SJ | 1 |
| Teo, M | 1 |
| Lim, KH | 1 |
| Choo, SP | 1 |
| Toh, HC | 1 |
| Wilkes, EA | 1 |
| Selby, AL | 1 |
| Cole, AT | 2 |
| Freeman, JG | 2 |
| Rennie, MJ | 1 |
| Khan, ZH | 2 |
| Yu, J | 1 |
| Liu, F | 1 |
| Sun, Z | 1 |
| Sun, M | 1 |
| Sun, S | 1 |
| Simpson, EJ | 1 |
| Holt, M | 1 |
| MacDonald, I | 1 |
| Pye, D | 1 |
| Austin, A | 1 |
| Chen, KC | 1 |
| Chang, YL | 1 |
| Pan, CT | 1 |
| Lee, YC | 1 |
| Kotoh, T | 1 |
| Dhar, DK | 1 |
| Masunaga, R | 1 |
| Tabara, H | 1 |
| Tachibana, M | 1 |
| Kubota, H | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
3 trials available for thalidomide and Cancer of Esophagus
| Article | Year |
|---|---|
Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers; Chemoradiotherapy; China; Down- | 2014 |
Poor tolerability of thalidomide in end-stage oesophageal cancer.
Topics: Aged; Aged, 80 and over; Cachexia; Double-Blind Method; Esophageal Neoplasms; Female; Humans; Male; | 2011 |
Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.
Topics: Aged; Aged, 80 and over; Basal Metabolism; Body Composition; Body Mass Index; Cachexia; Energy Intak | 2003 |
4 other studies available for thalidomide and Cancer of Esophagus
| Article | Year |
|---|---|
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophag | 2010 |
The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism.
Topics: Apoptosis; Cell Cycle; Cell Growth Processes; Cell Survival; Combined Modality Therapy; Esophageal N | 2011 |
Esophageal atypical carcinoid tumor with tracheal invasion.
Topics: Administration, Oral; Aged; Carcinoid Tumor; Combined Modality Therapy; Diagnosis, Differential; Eso | 2007 |
Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Topics: Animals; Endothelial Growth Factors; Esophageal Neoplasms; Female; Fibroblast Growth Factor 2; Human | 1999 |